HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

HER2+ breast cancer survival rates tell you how many women survive for a certain time after their diagnosis. ... Doctors use three markers to help define breast cancers and guide treatment.

Panelists discuss the rapidly evolving endocrine treatment landscape in oncology, emphasizing the shift toward personalized ...

The HER-2/neu oncogene encodes a 185 Kd tyrosine kinase (TK) receptor and belongs to the type 1 receptor family that includes the epidermal growth factor receptor, HER-3, and HER-4. These ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

The non-invasive study seeks to find whether or not cancer cells express certain markers for those with HR-/HER2+ breast cancer. The goal is to use that information to eventually lead to targeted ...

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer. AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced ...

I think in HER2+ breast cancer, it's much easier to do that because we know that the responses to first-line treatment can be so dramatic and to expect that is reasonable for somebody who you're ...

The stability of markers like HER2 in breast cancer makes it a potent target for ADCs, allowing for sequenced drug development. ADCs are not interchangeable; each has distinct features and side ...

Dynamics of the tumor marker (TM) cancer antigen 15.3 (CA 15.3) and its association with overall survival (OS) in patients (pts) with hormone-receptor ... Factors impacting treatment with a CDK4/6i in ...